Leerink Swann Downgrades Sarepta Therapeutic (SRPT) to Market Perform on Lack of FDA Clarity
Tweet Send to a Friend
Leerink Swann downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Outperform to Market Perform with a price target of $41.00 (from $45.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
